US2016068813A1PendingUtilityA1

Differentiation of adipose stromal cells into osteoblasts and uses thereof

52
Assignee: ARTECEL SCIENCES INCPriority: Dec 2, 1997Filed: Nov 13, 2015Published: Mar 10, 2016
Est. expiryDec 2, 2017(expired)· nominal 20-yr term from priority
A61P 43/00A61P 19/10A61P 19/08A61F 2002/30677C12N 2510/00A61F 2002/2835C12N 2501/155A61F 2310/00383C12N 5/0654A61F 2002/4648A61K 38/00A61K 48/00C12N 2506/1384C12N 2533/54C12N 2500/38C12N 2500/34C12N 2533/14C12N 2500/42A61F 2/28A61K 35/12A61F 2310/00293A61K 35/32A61F 2310/00365C12N 2502/1305A61F 2002/2817C12N 2506/13
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides methods and compositions for differentiating stromal cells from adipose tissue into cells having osteoblastic properties, and methods for improving a subject's bone structure. The methods comprise culturing stromal cells from adipose tissue in β-glycerophosphate and ascorbic acid and/or ascorbate-2-phosphate for a time sufficient to allow differentiation of said cells into osteoblasts. Such methods and compositions are useful in the production of osteoblasts for autologous transplantation into bone at a surgical site or injury. The compositions comprise adipose stromal cells, a medium capable of supporting the growth of fibroblasts and amounts of β-glycerophosphate and ascorbic acid and/or ascorbic-2-phosphate sufficient to induce the differentiation of said stromal cells into osteoblasts. The invention further provides methods of identifying compounds that affect osteoblast differentiation. Such compounds are useful in the study of bone development and in the treatment of bone disorders, including bone fractures and osteoporosis.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of differentiating adipose stromal cells into osteoblasts, comprising: culturing said cells in a composition comprising a medium capable of supporting the growth of fibroblasts and differentiation inducing amounts of β-glycerophosphate and ascorbic acid and/or ascorbic-2-phosphate. 
     
     
         2 . The method of  claim 1 , wherein said amounts are about 2-20 mM β-glycerophosphate and about 20-75 μM ascorbic acid and/or ascorbic-2-phosphate. 
     
     
         3 . The method of  claim 2  wherein said amounts are about 5-15 mM β-glycerophosphate and about 40-60 μM ascorbic acid and/or ascorbic-2-phosphate. 
     
     
         4 . The method of  claim 3 , wherein said amounts are about 10 mM β-glycerophosphate and about 50 μM ascorbic acid and/or ascorbic-2-phosphate. 
     
     
         5 . The method of  claim 1 , wherein said medium is selected from the group consisting of: DMEM, aMEM and BME. 
     
     
         6 . The method of  claim 1 , wherein said medium further comprises about 5-20% fetal calf serum. 
     
     
         7 . The method of  claim 1 , wherein said medium further comprises one or more bone morphogenetic proteins. 
     
     
         8 . The method of  claim 1  wherein said cells are mammalian. 
     
     
         9 . The method of  claim 8  wherein said cells are human. 
     
     
         10 . A method of improving a subject's bone structure, comprising:
 a. culturing adipose stromal cells in a composition which comprises a medium capable of supporting the growth of fibroblasts and differentiation inducing amounts of β-glycerophosphate and ascorbic acid and/or ascorbic-2-phosphate; and   b. introducing said osteoblasts into a surgery or fracture site of said subject.   
     
     
         11 . The method of  claim 10 , wherein said amounts are about 2-20 mM β-glycerophosphate and about 20-75 μM ascorbic acid and/or ascorbic-2-phosphate. 
     
     
         12 . The method of  claim 11 , wherein said amounts are about 5-15 mM β-glycerophosphate and about 40-60 μM ascorbic acid and/or ascorbic-2-phosphate. 
     
     
         13 . The method of  claim 12 , wherein said amounts are about 10 mM β-glycerophosphate and about 50 μM ascorbic acid and/or ascorbic-2-phosphate. 
     
     
         14 . The method of  claim 10 , wherein said adipose stromal cells are isolated from said subject. 
     
     
         15 . The method of  claim 10 , wherein said medium is selected from the group consisting of: DMEM, aMEM and BME. 
     
     
         16 . The method of  claim 10 , wherein said medium further comprises about 5-20% fetal calf serum. 
     
     
         17 . The method of  claim 10 , wherein said medium further comprises one or more bone morphogenetic proteins. 
     
     
         18 . The method of  claim 10 , wherein said subject is mammalian. 
     
     
         19 . The method of  claim 18 , wherein said subject is human. 
     
     
         20 . The method of  claim 10 , wherein said osteoblasts are introduced in admixture with a composition useful in the repair of bone wounds, bone defects and/or bone disorders. 
     
     
         21 . The method of  claim 10 , wherein a nucleotide sequence of interest is introduced into said adipose stromal cells or said osteoblasts.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.